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Abstract
Background: There is a paucity of literature on the referral outcome of patients seen in phase I
trial clinics in academic oncology centres. This study aims to provide information on the accrual
rate and to identify obstacles in the recruitment process.
Methods: A retrospective chart review was performed for all new patients referred and seen in
the phase I clinic at the Princess Margaret Hospital between January 2000 and June 2005. Data on
their demographics, medical history, and details of trial participation or non-entry were recorded.
Results: A total of 667 new phase I referrals were seen during the stated period. Of these patients,
197 (29.5%) patients were enrolled into a phase I trial, and 64.5% of them started trial within 1
month of the initial visit. About a quarter (165 of 667) of the patients referred were deemed
ineligible at their first visit, with the most frequent reasons for ineligibility being poor performance
status, unacceptable bloodwork, too many prior treatments and rapid disease progression. The
remaining 305 patients (45.7%) were potentially eligible at their initial visit, but never entered a
phase I trial. The main reasons for their non-entry were patient refusal, other treatment
recommended first, and lack of available trials or trial spots.
Conclusion: This study provides information on the clinical realities underlying a referral to a
phase I clinic and eventual trial enrollment. Better selection of patients, appropriate education of
referring physicians, and opening phase I trials with fewer restrictions on some criteria such as
prior therapy may enhance their recruitment rates.
Background
Phase I clinical trials evaluate the dosing and toxicities of
novel agents or combinations of agents in humans after
appropriate preclinical testing of safety, toxicology and
pharmacology. Oncology patients who have been referred
to the phase I trials clinic represent the unique subset of
patients who have exhausted standard treatment options,
yet continue to be functionally well. Because the risks
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associated with an investigational drug are unknown, and
the likelihood of therapeutic response is relatively small
[1], multiple studies have examined the motivations of
these patients for participating in phase I oncology trials.
While patients understand that it is not the purpose of
phase I studies, the potential for receiving personal thera-
peutic benefit remains the most important motivator for
trial participation [2-5]. However, in a recent review of
over 10,000 participants in phase I trials sponsored by the
National Cancer Institute between 1991 and 2002, the
average response rate for all agents was 10.6%, and agents
given in first-in-human trials produced a response rate of
only 4.8% [6].
Although clinical trials are a crucial step in the develop-
ment of new cancer treatments, their progress can be lim-
ited by low accrual rates. Barriers to the enrollment of
newly diagnosed cancer patients into phase I to III oncol-
ogy trials have been identified primarily as patient ineligi-
bility, lack of trials, and patient refusal [7,8]. However,
due to the distinctive nature of phase I clinical trials and
its patient population, the obstacles facing recruitment
into phase I studies are likely to be different than those
observed in oncology trials as a whole. Unfortunately, lit-
tle data exist to address this issue, even though clarifica-
tion of these obstacles could aid in improving and
streamlining the referral and evaluation process in phase
I oncology trials. Therefore, to address this question, we
retrospectively reviewed the course of patients from the
point of referral to trial entry or non-entry at the Princess
Margaret Hospital (PMH) phase I trials clinic over the past
5 years.
Methods
Chart Review
PMH is a tertiary care cancer center in Toronto, Canada,
with a well established phase I clinical trials program since
the late 1990s. All new patients referred to the phase I
clinic from January 2000 to June 2005 were identified
through clinic lists. Paper and/or electronic medical
records from the initial clinic visit to the time of trial entry
or non-entry were reviewed. Demographic data (gender,
age, postal code), medical information (tumor site,
number of prior chemotherapy regimens, performance
status, referring physician), details of trial participation
(trial entry date, trial entered, reasons for delayed entry
into trial), and/or circumstances around trial non-entry
were abstracted from physicians' clinical notes that were
dictated after each clinic visit. A delay in trial entry was
arbitrarily defined as greater than 1 month from the date
of the initial clinic visit to the date of starting study
drug(s).
Reasons for trial non-entry were mutually exclusive,
whereas the circumstances surrounding these reasons
could be multiple and were not mutually exclusive. The
reasons for trial non-entry were ranked in a hierarchical
order determined by consensus of the authors: refusal;
doing well and hence no trial treatment recommended;
no trials or spots available; other treatment recommended
first; initially a candidate but deteriorated while waiting;
lost to follow-up or reasons for non-entry unknown. The
reasons were ordered from the most to least limiting fac-
tor in patient accrual, as well as the clinical flow of a
patient's assessment in the phase I clinic. For instance, if a
newly referred patient with painful bony metastases
declined participation after the initial consultation, and
the phase I physician would have recommended palliative
radiotherapy before enrollment into any phase I trials, the
patient's refusal would be recorded as the only reason for
trial non-entry. Among 305 patients who were potentially
eligible but ultimately did not enter into a phase I trial,
only 73 (24%) had 2 or more reasons for trial non-entry
in this retrospective chart review.
All data abstracted were entered into a password-protected
database. This retrospective chart review study was
approved by the Research Ethics Board at the PMH, Uni-
versity Health Network. This project is internally funded
at the Princess Margaret Hospital and there are no external
funding sources.
Statistical and Study Analysis
Descriptive statistics, such as the mean, median, inter-
quartile range [IQR], standard deviation [sd] and propor-
tion were used to summarize patient characteristics and
outcomes. Distance to cancer centre in kilometers was cal-
culated as linear distance from the patients' listed resi-
dence to PMH via the forward sorting area (FSA). The FSA
is denoted by the first 3 alpha-numeric digits in the Cana-
dian postal code. The mid-point for each FSA was
obtained by using the postal code conversion file (Postal
code conversion file January 1999 edition, produced by
Statistics Canada) [9], obtained from the data library serv-
ice of the University of Toronto, Toronto, Canada.
Patients were assumed to reside at this central point of
their respective FSA.
Results
Patient Characteristics
Six hundred and sixty-seven patients were identified as
new referrals to the phase I oncology clinic. Patient demo-
graphics are summarized in Table 1. Interestingly, 68
(10.2%) chemonaïve patients were referred to the clinic.
These appeared to represent patients with malignancies
without effective standard treatments, or patients who
were considered for phase I trials that contained at least
one active agent in combination with novel agents.BMC Cancer 2006, 6:263 http://www.biomedcentral.com/1471-2407/6/263
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Referral Outcomes
The outcome of the patients from the point of referral is
summarized in Figure 1. Of the 667 new patients, 165
(24.7%) were ineligible for trial participation, the most
common reasons being poor performance status in 46%
(76), unacceptable bloodwork in 24% (40), too many
prior treatments in 13% (22), and rapidly progressive dis-
ease in 13% (22).
Out of the total of 667 patients, there were 96 (14.4%)
patients who declined participation in a phase I trial. The
circumstances given for declining participation were a
desire to pursue other treatments (n = 42; 44%), quality of
life reasons (n = 25; 26%), uncertainty of benefit (n = 21;
22%), trial burden (n = 16; 17%), not wanting further
treatment (n = 14; 15%) and uncertainty of toxicity (n =
11; 11%). Just over half (n = 23; 55%) of the 42 patients
who wished to pursue other treatments went on to receive
conventional treatments, but 12 (29%) received alterna-
tive treatments, and 7 (17%) went on another clinical
trial.
Besides patients' refusal to take part in phase I trials, the
other reasons for potentially eligible patients for not being
Table 1: Patient characteristics
Age Mean (sd) 56.5 (11.1)
Distance from PMH (km) Median (range) [IQR] 22.2 (0.6–1480.2) [12.7–42.7]
Gender Male:Female 339:328 (50.8:49.2)
Tumor site Breast 46 (6.9)
GI colorectal 172 (25.8)
GI non-colorectal 178 (26.7)
Genitourinary 36 (5.4)
Gynaecologic 74 (11.1)
Head and neck 23 (3.5)
Lung 57 (8.6)
Sarcoma 8 (1.2)
Skin and melanoma 11 (1.7)
Unknown primary 42 (6.3)
Multiple sites* 6 (0.9)
Other** 14 (2.1)
Number of prior regimens 0 68 (10.2)
1 210 (31.5)
2 186 (27.9)
3 116 (17.4)
4 52 (7.8)
5 24 (3.6)
6+ 11 (1.7)
PS 0 211 (31.6)
1 318 (47.7)
2 87 (13.0)
3 49 (7.4)
4 2 (0.3)
Entered on trial Yes:No 197:470 (29.5:70.5)
Referring physician PMH Oncologist 328 (49.2)
External Oncologist 310 (46.5)
Family Physician 12 (1.8)
Other Physician 13 (2.0)
Unknown 4 (0.6)
* Multiple sites were GI non-colorectal/gastric/lymphoma, GI non-colorectal/prostate, lung/breast, lung/esophageal, skin and melanoma/leukemia, 
unknown/prostate
** Others were adrenal [1], GI stromal [1], lymphoma [2], merkel cell [1] mesothelioma [3], mixed germ cell [1], neuroendocrine [2], 
pseudomyxoma [1], thyroid [1] and thymus [1]BMC Cancer 2006, 6:263 http://www.biomedcentral.com/1471-2407/6/263
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Patient outcome from the point of referral Figure 1
Patient outcome from the point of referral.BMC Cancer 2006, 6:263 http://www.biomedcentral.com/1471-2407/6/263
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enrolled were as follows. Of the 667 patients, 7 patients
(1.0%) were completely asymptomatic and as such, entry
into a trial was not recommended at the time. No trials or
available spots were available for 56 patients (8.4%), and
other treatments were recommended prior to a phase I
trial for 84 (12.6%) patients. Twenty-six patients (3.9%)
were in the process of being worked-up for a phase I trial,
but were unable to enroll due to deterioration in their
clinical conditions. Thirty-six patients (5.4%) were lost to
follow-up or it was unclear why they did not enter a trial.
Ultimately, 197 of 667 patients (29.5%) were entered into
a phase I trial. When analyzed by the year of accrual, the
proportions of patients who entered into a phase I trial
did not differ significantly over time. The enrollment per-
centages were 36% in 2000, 29% in 2001, 26% in 2002,
25% in 2003, 31% in 2004 and 29% in 2005. The major-
ity (127 of 197; 64.5%) of patients entered on a phase I
trial did so within 1 month of the initial clinic visit, with
a median time to trial entry of 2.4 weeks. Seventy of 197
patients (35.5%) experienced a delay in entering a trial,
with a median time to trial entry of 7.1 weeks. Common
reasons for a delayed trial entry included awaiting trial
cohorts to open (n = 31; 44%), waiting for trial work-up
(n = 18; 26%), needing time to consider (n = 10; 14%),
being on another treatment (n = 8; 11%) and patient pref-
erence (n = 8; 11%). Only 2 (3%) patients were delayed
because of lack of immediately available trials.
Subgroup Analysis
A breakdown of patient outcomes by patient characteris-
tics is shown in Table 2. Neither gender nor distance
appeared to affect patient outcome. However, age did
appear to be a factor as a greater proportion of ineligible
patients were over 70 years of age and patients less than 70
were more likely to be entered on trial. Tumor site was
also an important factor in affecting trial entry outcomes.
Tumor sites that were least likely to enter patients into
phase I trials included sarcoma, lung and breast cancers.
Ineligibility appeared to be the most prevalent reason for
non-entry in breast cancer and sarcoma patients. Lung
cancer patients appeared to be eligible for phase I trials at
initial consultation visits, but many were recommended
other treatments first, or had rapid deterioration after ini-
tially being eligible. Patients with multiple primary can-
cers were always excluded from trial entry. Additionally,
heavily pre-treated patients (3 or more previous chemo-
therapy regimens) and those with poor performance sta-
tus at the initial clinic visit (ECOG 2 or higher) were more
likely to be ineligible. Patients who had been referred to
the phase I trial clinic by oncologists at PMH were more
likely to go on trial and less likely to be ineligible when
compared to patients referred by external oncologists.
Discussion
This paper represents the first study to examine the referral
and enrollment process in the phase I trial setting. A pre-
vious study by Corrie et al. reviewed the factors limiting
the recruitment of 1,411 patients into phase I to III oncol-
ogy trials at the West Anglia cancer research network in the
United Kingdom [7]. Although their overall recruitment
rate was 19%, no trials were available for 40% of patients,
32% of patients were ineligible, and 19% of eligible
patients declined entry into a study. Another study by Lara
et al. at the University of California Davis Cancer Center
in the United States prospectively assessed patient accrual
into phase I to III oncology trials and reported an accrual
rate of 14% out of 276 patients [8]. Thirty-seven patients,
or 49% of those they considered eligible for available pro-
tocols, refused to participate for reasons including a desire
for other treatment, distance from the cancer center, and
insurance denial. While Lara et al. described financial bar-
riers to trial participation, these obstacles were not faced
by our patients due to the universal healthcare access pro-
vided by the Canadian medical system. However, recent
legislation in certain states such as California, Georgia,
and Massachusetts, ensures insurance coverage for phase I
clinical trials, making them more accessible to patients in
those states [10]. Thus, our results should be generalizable
to large academic centers with phase I programs outside of
Canada.
In our review of 667 new referrals to the phase I clinic at
PMH from 2000 to 2005, the overall accrual rate was
29.5%. While not directly comparable to those studies
examining recruitment to all three phases of clinical trials,
our accrual rate is substantially higher. The higher accrual
rate seen in our study likely reflects the fact that patients
were referred to our dedicated phase I clinic with the
expressed intent of participating in a phase I trial. How-
ever, 24.7% of patients were still ineligible, 14% declined
to enter a trial, 12.6% were recommended another treat-
ment prior to a clinical trial, and 8.4% were unable to par-
ticipate due to a lack of available trials or open cohorts.
These results suggest that patient recruitment could be fur-
ther improved by reducing the impact of several of these
factors.
Often characterized as desperate and willing to undergo
any treatment for a small chance of benefit, it seems sur-
prising that 14% of newly referred patients, or 19% of eli-
gible patients, declined participation in a phase I trial.
However, this is similar to the rate reported by Corrie et al.
[7], and lower than that reported by Lara et al [8]. Patients
had multiple reasons in deciding not to participate, the
most common of which was the desire to pursue other
treatments, similar to the finding of Lara et al [8]. How-
ever, other important reasons included quality of life pur-
poses, the uncertainty of benefit and toxicity, trial burden,B
M
C
 
C
a
n
c
e
r
 
2
0
0
6
,
 
6
:
2
6
3
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
4
0
7
/
6
/
2
6
3
P
a
g
e
 
6
 
o
f
 
9
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
) Table 2: Breakdown of patient outcome by patient characteristics
N Entered on Trial 
(% of Row Total)
Ineligible
 (% of Row Total)
Refused
 (% of Row Total)
Other Treatment Suggested First/No Spots 
Available/Initially Eligible but Deteriorated 
(% of Row Total)
Doing Well, Treat when Progress/Unclear/Lost 
(% of Row Total)
N 667 29.5 24.7 14.4 24.9 6.5
Age Mean (sd)^ 667 56.6 (10.3) 57.3 (11.5) 57.8 (11.3) 54.3 (10.4) 58.4 (14.0)
% 70+ 75 21.3 30.7 17.3 16.0 14.7
%<70 592 30.6 24.0 14.0 26.0 5.4
Distance from 
PMH (km)
Median [IQR]^ 667 21.9 [12.6–38.2] 21.7 [14.2–42.7] 20.7 [12.6–35.5] 28.2 [12.6–57.6] 22.2 [12.7–59.5]
Gender Male 339 30.1 23.9 12.7 26.0 7.4
Female 328 29.0 25.6 16.2 23.8 5.5
Tumor site Breast 46 23.9 39.1 15.2 19.6 2.2
GI colorectal 172 23.8 25.0 14.0 30.2 7.0
GI non-colorectal 178 33.7 22.5 16.3 20.8 6.7
Genitourinary 36 30.6 27.8 13.9 19.4 8.3
Gynaecologic 74 44.6 17.6 13.5 23.0 1.4
Head and neck 23 56.5 4.4 13.0 17.4 8.7
Lung 57 17.5 24.6 10.5 38.6 8.8
Sarcoma 8 12.5 37.5 12.5 25.0 12.5
Skin/melanoma 11 27.3 27.3 9.1 18.2 18.2
Unknown primary 42 26.2 26.2 14.3 26.2 7.1
Multiple sites 6 0.0 100.0 0.0 0.0 0.0
Other 14 21.4 21.4 28.6 21.4 14.3
Number of prior 
regimens
0 68 47.1 20.6 14.7 14.7 2.9
1 210 32.9 20.5 14.8 25.7 6.2
2 186 24.2 25.3 14.5 26.9 9.1
3+ 203 25.1 30.1 13.8 25.6 5.4
ECOG 0 211 43.6 9.0 16.1 24.2 7.1
1 318 28.6 17.3 16.0 29.6 8.5
2 87 14.9 49.4 12.6 21.8 1.2
3+ 51 2.0 94.1 0.0 3.9 0.0
Referring 
physician
PMH Oncologists 328 38.4 21.3 15.9 21.3 3.1
External 
Oncologists
310 19.0 29.4 12.6 29.0 10.0
Others/Unknown 29 41.4 13.8 17.2 20.7 6.9
^ Entries in these rows are in units as listedBMC Cancer 2006, 6:263 http://www.biomedcentral.com/1471-2407/6/263
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and the desire to have no more active treatments. This
finding suggests that many phase I patients do compre-
hend the requirements and objectives of study participa-
tion. Although phase I trial physicians are the best
qualified to help patients make this decision, educating
patients about the basics of phase I trials prior to their
referral may help some patients determine then that it is
something they do not wish to pursue. This would, in
turn, make more spots available for eligible and interested
patients, as well as shorten the waitlist to be seen in phase
I clinic.
Although it is usually thought that patients are referred for
phase I trials only after exhausting all other treatment
options, a remarkable 12.6% of newly referred patients, or
16.7% of eligible patients, were recommended another
treatment prior to a phase I study. Clinical experience
shows that trial physicians may make such a suggestion if
they feel that another treatment is better at providing
symptomatic control, or can provide more benefit than
the 5 to 10% response rate obtained from an experimental
agent. Most of these patients are informed that they can be
reevaluated for a phase I trial after they complete the rec-
ommended treatment, but unfortunately, the vast major-
ity of them are unable to do so. Because the clinical course
of these end-stage patients is unpredictable, the window
of opportunity for starting a phase I trial may be limited.
The delay involved in waiting for an appointment, being
assessed in phase I clinic and then undergoing another
therapy may be sufficient time for a patient's clinical sta-
tus to deteriorate, thus rendering the patient ineligible for
trial entry. Therefore, in order to expedite patient accrual
into trials, it is important to ensure that all treatments
have been exhausted and all symptoms are well managed
prior to referral to the phase I clinic. Interestingly, 47% of
chemonaïve patients in our study entered into phase I tri-
als (data not shown), and were less likely to be recom-
mended another treatment first (15%). These figures
indicate that these were indeed the patients with malig-
nancies for which no effective standard treatments exist,
or alternatively these patients were accrued into phase I
trials containing at least one active approved anticancer
agent.
Lack of trial availability or open cohorts prevented 8.4%
of newly referred, eligible and interested patients in our
study from participating in a trial. Additionally, it was the
most common reason for a delay in patients who eventu-
ally entered a trial. Given that trials were not available for
40 to 50% of patients in other studies [7,8], our result is
intriguing, although the phase I trial setting is different in
that trials are neither site nor stage specific, allowing
patients to enter into any open trials. Also, in contrast to
the other studies which reviewed experiences in general
cancer clinics, patients in our study were seen in a dedi-
cated phase I clinic in which enrollment into a phase I
trial is the main reason for the referral, and the physician
and nursing staff are well aware of trial availability. None-
theless, if more trials and spots were made available, all
eligible and interested patients could be accommodated
and the amount of delay in starting a trial reduced.
While nearly one quarter of newly referred patients were
deemed ineligible to enter a phase I trial for various rea-
sons, the subgroup analysis also identified specific patient
factors that were more likely to preclude trial entry. Eld-
erly patients 70 years of age or over appeared less likely to
be eligible for and enter phase I trials when compared to
patients less than 70 years old. The finding that elderly
patients are underrepresented in oncology trials, includ-
ing phase I studies, has been previously documented
[11,12]. Tumor site also affected clinical outcome, as
breast cancer patients in particular were more likely to be
ineligible. A further review of the data indicates that 72%
(13/18) of the ineligible breast patients were excluded
from trial entry because they had received too much prior
treatment. The number of sarcoma patients in this study
was too small to draw any conclusions about their reasons
for ineligibility. Certainly, those with multiple primary
cancers were always excluded from phase I trials and
therefore should not be referred to the clinic for assess-
ment. Additionally, patients with poor performance status
(ECOG >2) were very unlikely to enter a trial, which is fur-
ther supported by our finding that this was the most com-
mon reason for ineligibility. Heavily pre-treated patients
were also unlikely to enter a trial, and accounted for 13%
of patients who were excluded by trial entry criteria.
Although there exist trials without restrictions on the
number of prior lines of chemotherapy, this obstacle
could be overcome by increasing the number of these tri-
als. Especially in the current era of targeted agents where
bone marrow toxicity is less common, the amount of
prior treatment is less of a concern. Furthermore, trials
with unrestricted prior therapy are generally easier to
complete. Although a relaxation of some trial eligibility
criteria could increase accrual rates, trial investigators
would need to balance this with clinical or scientific con-
cerns, such as avoiding undue toxicity or maintaining a
more homogenous patient group.
Finally, being referred by an external physician appeared
to decrease a patient's chances of entering a trial as more
of these patients were ineligible or were recommended
another treatment first. When compared to patients
referred by PMH physicians, those referred by external
physicians were more likely to have an ECOG status of 3
(4.6% vs. 10.7%) and thus be excluded from trial entry
due to poor performance status (40% vs. 51.7%). PMH
physicians may have the benefit of being better aware of
available trials at the time of referral, thus allowing moreBMC Cancer 2006, 6:263 http://www.biomedcentral.com/1471-2407/6/263
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of their patients to be enrolled. However, regardless of the
referral source, educating referring physicians about the
factors and characteristics that make patients ineligible
may reduce the number of inappropriate referrals. Addi-
tionally, having a triage system to pre-screen referral
records, such as prior therapy, laboratory results, concom-
itant medications, etc. may also help to ensure that more
potentially eligible patients are seen in the phase I clinic.
As a retrospective study, our study has certain limitations.
Although physicians' clinic notes are a useful and easily
accessible source of information, they are hardly a com-
plete record of all the complexities surrounding a patient's
assessment or decision to undergo or decline a clinical
trial. Certainly, in the case of 7 patients, it was unclear as
to why they did not enter a trial, as well as in 10 patients
in which no reason for declining trial entry was given.
Additionally, 29 patients were lost to follow-up.
In examining the patterns of referral and enrollment in
the phase I clinic over the past five years, our study pro-
vides future patients and physicians with better insight
into the clinical realities underlying a referral to the phase
I clinic. Our results identify factors and characteristics that
hinder patient accrual, the knowledge of which may be
helpful in defining referral guidelines and developing
strategies to maximize patient recruitment.
Conclusion
This study reviews the referral experience from the phase I
clinic at the Princess Margaret Hospital, with focus on the
barriers that influence eventual trial enrollment. Better
selection of patients, appropriate education of referring
physicians, and opening phase I trials with fewer restric-
tions on some criteria such as prior therapy may enhance
their recruitment rates.
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